Department of Defense Fiscal Year 2004 Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA).

The summary for the Department of Defense Fiscal Year 2004 Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA). grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense Fiscal Year 2004 Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA).: The objectives of the FY04 CMLRP are to improve (1) the understanding of the basic science of CML, (2) the diagnosis of CML, (3) the treatment of CML, and (4) the quality of life for individuals and their families living with CML. The intent of the Therapeutic Development Award mechanism is to sponsor the preclinical assessment of therapeutics, as well as the development of tools for the preclinical evaluation in model systems for CML. The overall goal of this award mechanism is to allow CML investigators to develop the means to analyze preclinical efficacy of novel and existing agents and/or to generate the preclinical data necessary to conduct clinical trials after completion of the proposed research. The Therapeutic Development Award is restricted to research in CML. The proposed studies are expected to be empirical in nature and product driven, but may have a hypothesis-driven approach provided the focus is on therapeutics. It is anticipated that the agents, model systems, or data generated from these awards will lead to the advancement of therapeutics novel to CML and to the development of a broad platform on which to test future therapies. The ultimate goal is to significantly move closer to the development of new therapeutics for CML.